Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 53 of 65 · 3097 articles
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
Changes in gut permeability are thought to relate to intestinal barrier function and symptoms in UC and IBS-D. If Aquamin alters permeability, it could suggest a mechanism for symptom or disease-modifying effects and...
This trial tests mirikizumab (an anti–IL-23p19 biologic) alone and with an oral agent in adults with moderate–severe UC or CD, which could expand treatment options if later-phase trials are successful.
This trial tests whether adding an FXR agonist (LY4395089) to mirikizumab improves endoscopic response in people with moderate–severe Crohn's disease. Results could influence future combination treatment strategies and...
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
This trial tests a common real-world question: switching from IV induction to subcutaneous vedolizumab maintenance in adults with moderate-to-severe UC or CD and measures short-term remission and longer-term treatment...
Surgery is common in Crohn’s disease and different types of resections carry different short-term risks.
Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
If you have newly diagnosed Crohn’s disease, this study suggests sacroiliac joint inflammation or structural SIJ changes can already be present and may relate to microscopic (histologic) intestinal activity.
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
Zinc deficiency is common in UC, and this study suggests that changes in zinc‑dependent enzyme activity in the gut lining are linked with local inflammation. If confirmed, mucosal enzyme activity might help explain...
Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.
Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
The study links depleted fatty acid oxidation metabolites—especially butyrate—to impaired regulatory T cell development in IBD, suggesting a metabolic pathway that may influence immune tolerance and disease activity.
A traditional medicine formulation (Hudi capsules) relieved colitis signs in mice and appears to stimulate Wnt/β-catenin–dependent epithelial regeneration, which could point to new therapeutic directions for mucosal...
A new biologic (duvakitug) targeting TL1A showed higher clinical remission at 14 weeks than placebo in a phase 2b trial of adults with moderately to severely active ulcerative colitis, which could expand future treatment...
The review suggests MSCs and their exosomes can change the gut microbiome, a factor implicated in IBD and liver disease, pointing to a potential new therapeutic approach. Patients and clinicians interested in future IBD...
If therapies that restore intestinal barrier function can be reliably tested and measured, future treatments might be developed that specifically target barrier healing — a mechanism linked to symptom relief and possibly...
The study shows that more children worldwide are living with early-onset IBD even as mortality has fallen, and it highlights persistent socioeconomic disparities—important for families and clinicians tracking pediatric...
Markers of systemic inflammation (CRP and ESR) were consistently higher in people with obesity across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis, suggesting body weight may influence...
Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
Cure8 found this source from BMC Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, AI and data science, and Colonoscopy. Open the original article for the full...
This large, population-based study tests whether exposure to outdoor artificial light at night is linked to getting IBD or to later health-care use. Understanding environmental factors that might influence IBD risk or...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...
Researchers tested manumycin A in a standard mouse colitis model and observed reduced inflammation and tissue injury, suggesting the compound might be a candidate for further IBD drug development.
New PET tracers like FAPI could better detect fibrosis and stromal activity than standard FDG-PET, which may improve imaging of fibrostenotic Crohn's disease. For people with IBD, improved imaging might eventually help...
Cure8 found this source from Journal of gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Biomarkers, and Research and clinical trials. Open the original article...
The paper identifies a specific bacterial metabolite-receptor pathway (succinic acid → SUCNR1 → NF-κB) by which Fusobacterium nucleatum may worsen intestinal inflammation, suggesting new targets for IBD research and...
The oral microbiome can influence gut microbes and inflammation; understanding this link could lead to new diagnostic markers (saliva) or combined dental–gastroenterology care approaches relevant to people with IBD.
New or improved fluorescent probes could enable more sensitive, noninvasive imaging of biochemical changes in the gut, which may aid research, earlier diagnosis, or monitoring of IBD and colorectal cancer.
This review found that children with atopic dermatitis have a modestly higher risk of later developing IBD (both Crohn’s disease and ulcerative colitis). Awareness of this association may help clinicians and families...
ER stress in intestinal epithelial cells is proposed as a key molecular mechanism in UC development; targeting ER pathways (notably IRE1β) could eventually lead to new treatments that strengthen the gut barrier and...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Colorectal cancer, and Research and clinical trials. The original article is from Cell Cycle.
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.
People with Crohn’s may be interested because the study links oxidative stress and specific genes to disease activity, which could inform future biomarkers or treatments. It helps explain biological pathways behind...
The report suggests adding acupuncture to anti-TNF therapy may improve short-term symptom control and mucosal healing and reduce early colectomy risk for a TCM-defined subgroup of ulcerative colitis patients, which could...
IL-38 and a genetic variant (rs7599662) were linked to ulcerative colitis in this study, suggesting a possible new biomarker or therapeutic target. If validated, this could help researchers better understand UC...
This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help...
This trial tests several investigational long-acting antibody treatments (as monotherapies and combinations) for adults with moderate to severe ulcerative colitis using histologic and clinical remission endpoints —...
This trial could expand approved treatment options for children with moderate to severe UC by testing the safety, pharmacokinetics, and maintenance dosing of risankizumab in pediatric age groups.
A new NIR-II-emitting MOF probe could enable deeper, higher-contrast fluorescence imaging of inflamed gut tissue and might be developed as a targeted delivery/imaging agent relevant to IBD research and future...
